Yongan Pharmaceutical (002365.SZ) released results for the first three quarters, with net profit of 114 million yuan to mother, an increase of 348.81% over the previous year

According to Zhitong Finance App, Yongan Pharmaceutical (002365.SZ) released its report for the third quarter of 2026. The company achieved operating income of 949 million yuan in the first three quarters, up 64.38% year on year; net profit attributable to shareholders of listed companies was 114 million yuan, up 348.81% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 109 million yuan, up 2009.75% year on year; basic earnings per share were 0.3958 yuan. The company's revenue growth was mainly due to the increase in sales volume and price of its main product, taurine, and the increase in revenue from health products in the current period.